World-first discovery paves way to new cancer treatment

Australian researchers have discovered a new way to target an aggressive childhood cancer, neuroblastoma, one of the most common and dangerous cancers in young children.

The discovery may also have important implications for some other aggressive cancers in children, including certain brain tumours, as well as some adult cancers, including ovarian and prostate cancer.

The new research, led by scientists at Children’s Cancer Institute and published in Nature Communications, has discovered that a cellular protein called ALYREF plays a crucial role in accelerating the effects of the cancer driver gene, MYCN, in neuroblastoma.

Scientists have known for some time that the one third of children with neuroblastoma who have very high levels of MYCN in their cancer cells have a much poorer prognosis. However, MYCN has proven to be an unreachable target for drug design. Instead, scientists have turned their attention to finding other molecules that work in close partnership with MYCN.

In the new research, Children’s Cancer Institute scientists have shown that MYCN depends on ALYREF to drive the growth of neuroblastoma cells. According to Dr. Zsuzsi Nagy and lead researchers Professor Glenn Marshall AM and Dr. Belamy Cheung, this is a world-first discovery.

“We have been able to show for the first time that ALYREF binds to and actually controls MYCN function in neuroblastoma cells,” explains Professor Marshall. “This means we now have a new molecule that we can target… a new way to get at MYCN and stop it from driving aggressive cancer growth.”

Working with neuroblastoma cells, Professor Marshall and his team found that ALYREF bound to MYCN directly to switch on another protein, USP3, which prevents MYCN being degraded. This maintains the extremely high levels of MYCN needed to drive the cancer, and so acts as an accelerant. These findings strongly suggest that ALYREF inhibition could interrupt this cycle and prove to be a very valuable new therapeutic strategy for high-risk neuroblastoma.

The next step will be to develop a potent and specific ALYREF inhibitor—a drug capable of inhibiting the actions of this molecule ? and to test this in laboratory models

“This research provides new knowledge as a basis for drug discovery,” said Dr. Cheung. “Once we find a suitable drug candidate, we can take this to clinical trial in children with high levels of MYCN and ALYREF in their tumours.”

Excitingly, targeting ALYREF may also prove to be a useful therapeutic strategy for other types of cancer which, like high-risk neuroblastoma, are known to be MYCN-driven. These include blood cancers, medulloblastoma, glioblastoma, retinoblastoma, ovarian cancer, Wilms’ tumour, and neuroendocrine prostate cancer. Further research will be needed to explore this potential.

Provided by
Children’s Cancer Institute Australia

• About the Author
• Latest Posts

About healthfortnight

• COVID case rates hit new high for England, study finds - April 7, 2022
• Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
• SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
• Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
• Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
• Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
• LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
• ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
• No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
• Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022